CD39 + tissue-resident memory CD8 + T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36026440/
Despite being a standard treatment option in breast cancer, immune checkpoint inhibitors (ICIs) are only efficacious for a subset of patients. To gain a better understanding of the antitumor immune...
Conclusion: Our study indicates that CD39 TRM cells with a clonal overlap across compartments are key players in antitumor immunity in breast cancer.
Overexpression of FRAT1 protein is closely related to triple-negative breast cancer
Source : https://astr.or.kr/DOIx.php?id=10.4174/astr.2022.103.2.63
Overexpression of FRAT1 protein is closely related to triple-negative breast cancer Young-Sin Ko Wan-Seop Kim 2 , 4 , 3 and 1Department of Surgery, Konkuk University School of Medicine, Seoul,...
Conclusion: FRAT1 was overexpressed in breast cancer compared to normal tissue, and it may be involved in the progression of breast cancer malignancy. This study provides suggestive evidence of the prognostic role of FRAT1 in breast cancer and the therapeutic target for TNBC.
Relevance: In this cross-sectional study, we describe and decompose changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alfa, and pegfilgrastim.
"A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring"
Source : https://www.sciencedirect.com/science/article/pii/S1570023222003075?via=ihub
TDM could optimize breast cancer treatments based on abemaciclib and letrozole. * A LC-MS method for abemaciclib, M2, M20 and letrozole has been developed. * The presented method was fully...
Relevance: The method was applied to analyze plasma samples from patients enrolled in a clinical trial, collected at Cmin. Incurred sample reanalysis was performed on a set of 30 samples, confirming the reproducibility of the analytical method.
Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35804935/
Cyclin-dependent kinase 4/6 inhibitors are the standard of care for hormone receptor-positive metastatic breast cancer. This retrospective study reports on genomic biomarkers of CDK 4/6i resistance utilizing genomic data acquired...
Conclusion: In this retrospective analysis, genomic biomarkers including FGFR1 amplification, PTEN loss, and DNA repair pathway gene mutations showed significant associations with shorter PFS for patients receiving CDK4/6 inhibitor therapy.
-
Albert Dekker4yrThis is particularly important on adjuvant setting. Patients who are HRD positive should received adjuvant PARP not CK4/6
-
Breast Cancer Connect4yrThanks, All, for your wonderful input! Does anyone else see clinical value in the findings of this study? Will more data points on genomic biomarkers change your approach?